HOME >> BIOLOGY >> NEWS
48-wk resistance data comparing GW433908 boosted & unboosted with nelfinavir

Boston (Feb. 11, 2003) Forty-eight-week data were presented here today from two Phase III studies (NEAT and SOLO) of treatment-nave patients with HIV infection, evaluating the resistance profile of the investigational protease inhibitor (PI) GW433908 (908) dosed twice a day (BID) or 908 boosted with the PI ritonavir (908/r) dosed once a day (QD) compared to the PI nelfinavir (NFV) BID. The medications in both studies were administered as part of combination therapy that also included 300 mg abacavir (ABC) BID and 150 mg lamivudine (3TC) BID. ABC and 3TC are nucleoside reverse transcriptase inhibitors (NRTIs).

908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX). In the SOLO study, no patients (0 percent) in the 908/r arm, out of 32 subjects experiencing virologic failure or with ongoing viral replication, had detectable primary or secondary PI mutations. In contrast, 27 of 54 patients (50 percent) in the NFV arm developed primary or secondary PI mutations. The clinical relevance of the resistance data is currently under evaluation.

In the NEAT study, 5 of 29 patients (17 percent) who experienced treatment failure in the unboosted 908 arm had mutations characteristic of APV resistance. NFV-selected mutations were observed in 7 of 26 patients (27 percent) who experienced virologic failure in the nelfinavir arm.

In the NEAT study, mutations selected by 908 were consistent with the spectrum of mutations selected by APV. Mutations detected in patients taking unboosted 908 included I54L/M, M46I and V32I+I47V. Mutations observed with other PIs (D30N, I54V, V82A/T/S, L90M) were not detected among patients taking unboosted 908.

In the SOLO study, there was a statistically significant difference between 908/r QD and NFV BID in the incidence of treatment emergent mutations selected by either the study PI (P<0.001) or the NRTIs ABC and
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
11-Feb-2003


Page: 1 2 3

Related biology news :

1. Master of antimalarial resistance
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Evolvability could be a driving force in drug resistance
4. Insecticide resistance: A constraint on evolutionary change
5. New drug shows promise against Gleevec resistance in mice
6. New milestones on the path to conquering HIV drug resistance (AIDS)
7. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
8. Antibiotic resistance risk from triclosan questioned
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Researchers string together players in pesticide resistance orchestra
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... ... November 14, 2018 , ... uBiome, the ... and medical director of Flatiron Functional Medicine to its Medical Advisory Board. Joining ... will bring to uBiome extensive experience in treating the root causes of disease, ...
(Date:11/14/2018)... ... November 14, 2018 , ... In recognition of World Diabetes Day, ... awareness and advocacy. The company is reaching out to help educate patients and the ... the importance of vision testing for people with the disease. , The American Diabetes ...
(Date:11/13/2018)... ... November 13, 2018 , ... ... instrumentation with capability to resolve complex sample matrix and to allow identification ... chromatograph (HRAM LC/MS) have been used extensively for structural elucidation of unknown ...
Breaking Biology News(10 mins):
(Date:11/9/2018)... ... November 08, 2018 , ... ... PhD, co-Founder, Chief Executive Officer and President of Andes Biotechnologies, to its Scientific ... world, Dr. Valenzuela brings to uBiome expertise on the genetic studies of hepatitis ...
(Date:11/7/2018)... ... November 07, 2018 , ... Since September of this year, ... of the adult tissue stem cell counting problem in stem cell medicine and ... intensifying this effort with new educational publications and presentations at clinical trial supply ...
(Date:11/5/2018)... ... 05, 2018 , ... Frederick National Laboratory for Cancer Research ... science research and education in the Frederick County area. , Frederick Center ... to STEM-based undergraduate and graduate degree and certificate programs offered by partnering colleges ...
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades has completed ... Like (TAL) effector code technology for applications in advancing research in epigenetic technology. ... plants. Since its discovery in 2009, the efficacy of TAL effector-based DNA targeting has ...
Breaking Biology Technology:
Cached News: